Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection

Antimicrob Agents Chemother. 2012 May;56(5):2518-23. doi: 10.1128/AAC.05947-11. Epub 2012 Feb 6.

Abstract

Recent exposure to azoles is an important risk factor for infection with fluconazole-resistant Candida spp., but little is known about the role of antibacterial drug exposure in the emergence of drug-resistant Candida. We did a prospective nationwide surveillance study of candidemia in Israel and analyzed the propensity score-adjusted association between antifungal and antibacterial drug exposure and bloodstream infection with C. glabrata and fluconazole-resistant Candida isolates. Four hundred forty-four episodes of candidemia (450 Candida isolates, 69 [15%] C. glabrata isolates, and 38 [8.5%] fluconazole-resistant isolates) from 18 medical centers in Israel were included. C. glabrata bloodstream infection was strongly associated with recent metronidazole exposure (odds ratio [OR], 3.2; P < 0.001). Infection with a fluconazole-resistant isolate was associated with exposure to carbapenems, trimethoprim-sulfamethoxazole, clindamycin, and colistin (odds ratio, 2.8; P = 0.01). The inclusion of antibacterial drug exposure in a multivariable model significantly enhanced the model's predictive accuracy for fluconazole-resistant Candida bloodstream infection. Our findings may be relevant to the selection of empirical antifungal treatment and broaden the scope of antibiotic-associated collateral damage.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / adverse effects*
  • Antifungal Agents / administration & dosage
  • Antifungal Agents / therapeutic use
  • Bacteria / drug effects
  • Bacteria / growth & development
  • Bacterial Infections / drug therapy*
  • Bacterial Infections / microbiology
  • Candida glabrata / drug effects*
  • Candida glabrata / physiology
  • Candidemia / drug therapy*
  • Candidemia / etiology
  • Candidemia / microbiology
  • Candidiasis / drug therapy*
  • Candidiasis / etiology
  • Candidiasis / microbiology
  • Carbapenems / administration & dosage
  • Carbapenems / adverse effects
  • Clindamycin / administration & dosage
  • Clindamycin / adverse effects
  • Coinfection
  • Colistin / administration & dosage
  • Colistin / adverse effects
  • Drug Resistance, Fungal
  • Female
  • Fluconazole / administration & dosage
  • Fluconazole / therapeutic use*
  • Humans
  • Israel
  • Microbial Sensitivity Tests
  • Middle Aged
  • Odds Ratio
  • Prospective Studies
  • Risk Factors
  • Trimethoprim, Sulfamethoxazole Drug Combination / administration & dosage
  • Trimethoprim, Sulfamethoxazole Drug Combination / adverse effects

Substances

  • Anti-Bacterial Agents
  • Antifungal Agents
  • Carbapenems
  • Clindamycin
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Fluconazole
  • Colistin